Added to YB: 2024-02-16
Pitch date: 2024-02-15
NVO [bullish]
Novo Nordisk A/S
-69.81%
current return
Author Info
No bio for this author
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 784.68
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
growth
Novo Nordisk: These Bold Moves Point Toward Upside
NONOF: Novo Nordisk a strong buy for 2024. Weight loss drug market to hit $100B by 2030, 15M US adults on meds. $8.3B investment to meet demand, cut costs. Wegovy reduces CV risk 20%. Double-digit sales & profit growth in 2023, optimistic 2024 outlook. Partnerships w/ Regeneron, Omega, Cellarity for innovative treatments. High valuation reflects strong growth expectations.
Read full article (8 min)